Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M543Revenue (TTM) $M120Net Margin (%)7.6Altman Z-Score7.2
Enterprise Value $M551EPS (TTM) $1.3Operating Margin %11.3Piotroski F-Score5
P/E(ttm)63.0Beneish M-Score-2.1Pre-tax Margin (%)11.3Higher ROA y-yY
Price/Book6.510-y EBITDA Growth Rate %0.2Quick Ratio1.6Cash flow > EarningsN
Price/Sales4.75-y EBITDA Growth Rate %16.8Current Ratio2.8Lower Leverage y-yN
Price/Free Cash Flow570y-y EBITDA Growth Rate %51.1ROA % (ttm)8.0Higher Current Ratio y-yY
Dividend Yield %--PEG3.7ROE % (ttm)13.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M6.9ROIC % (ttm)12.5Gross Margin Increase y-yN

Gurus Latest Trades with HSKA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSKAMario Gabelli 2016-09-30 Reduce$38.41 - $56.16
($49.3)
$ 78.6960%Reduce -3.98%48,200
HSKAMario Gabelli 2015-12-31 Reduce$28.39 - $39.76
($33.34)
$ 78.69136%Reduce -0.40%50,200
HSKAMario Gabelli 2015-09-30 Reduce$28.52 - $35.24
($32.51)
$ 78.69142%Reduce -3.82%50,400
HSKAMario Gabelli 2015-03-31 Reduce$16.32 - $25.94
($21.12)
$ 78.69273%Reduce -1.13%52,400
HSKAMario Gabelli 2012-12-31 Add$7.96 - $9.54
($8.71)
$ 78.69803%Add 29.08%62,135
HSKAMario Gabelli 2012-09-30 Add$7.78 - $11.3
($9.4)
$ 78.69737%Add 50.73%48,135
HSKAMario Gabelli 2012-06-30 Add$10.9 - $12.85
($11.86)
$ 78.69563%Add 56.54%31,935
HSKAMario Gabelli 2011-06-30 Add$6.12 - $9.96
($8.14)
$ 78.69867%Add 31.85%20,700
HSKAMario Gabelli 2011-03-31 Buy $4.79 - $6.83
($5.97)
$ 78.691218%New holding15,700
HSKAMario Gabelli 2010-12-31 Sold Out $0.415 - $0.53
($0.45)
$ 78.6917387%Sold Out0
HSKAMario Gabelli 2010-09-30 Add$4.4 - $6.6
($5.1)
$ 78.691443%Add 14.51%21,070
HSKAMario Gabelli 2010-06-30 Reduce$6.2 - $9
($7.53)
$ 78.69945%Reduce -16.63%18,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSKA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HSKA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
NAPOLITANO JASON ACOO, Chief Strategist and Sec. 2017-01-10Sell5,000$74.735.3view
GORDON G IRWINDirector 2016-11-29Sell3,000$66.1119.03view
McMahon JohnVP, CFO 2016-11-28Sell1,999$65.6419.88view
Lippincott RodEVP, Comp. Animal Health Sales 2016-11-22Sell5,000$64.8521.34view
Asakowicz SteveEVP, Comp. Animal Health Sales 2016-11-07Sell5,000$6129view
McGinley Michael JPresi, Biologic. & Pharm. 2016-11-07Sell9,998$60.1230.89view
NAPOLITANO JASON ACOO, CFO, EVP and Secretary 2016-09-01Sell5,000$52.5349.8view
Wilson Kevin S.CEO and President 2016-08-29Sell20,000$51.851.91view
McMahon JohnVP, Fin. Oper. & Controller 2016-08-24Sell137$51.353.39view
Asakowicz SteveEVP, Comp. Animal Health Sales 2016-08-09Sell4,698$52.5549.74view

Quarterly/Annual Reports about HSKA:

News about HSKA:

Articles On GuruFocus.com
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Heska's Still has Room to Run Aug 19 2016 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 

More From Other Websites
Incyte Treats First Patient in Phase II GVHD Study on Jakafi Jan 02 2017
Abbott Labs to Close St. Jude Acquisition Later this Week Jan 02 2017
HESKA CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 30 2016
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate Dec 30 2016
Corbus Concludes Phase II study of Cystic Fibrosis Candidate Dec 30 2016
Achillion Receives $15M from J&J for HCV Study Enrolment Dec 29 2016
Shire Gets FDA Approval for Label Expansion of Adynovate Dec 28 2016
Apricus Launches Vitaros in Lebanon for Erectile Dysfunction Dec 28 2016
Neothetics (NEOT) Begins Phase II Study on Lead Candidate Dec 28 2016
Horizon's Rare Disease Drug Quinsair Launched in Canada Dec 27 2016
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug Dec 23 2016
Celgene's Otezla Gains Positive Recommendation from NICE Dec 23 2016
Roche (RHHBY) Hemophilia A Drug Positive in Phase III Dec 23 2016
Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo Dec 22 2016
Incyte/Merus Ink Collaboration for Bispecific Antibodies Dec 22 2016
Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU Dec 21 2016
Juno Gets Breakthrough Therapy Status for Lymphoma Drug Dec 21 2016
ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint Dec 21 2016
J&J Files for FDA Approval of Simponi Aria Label Expansion Dec 21 2016
Amgen Files for Approval of Osteoporosis Drug in Japan Dec 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)